Ever-Growing USA on MSN11h
Retratutide: Eli Lilly’s Groundbreaking Drug for Obesity & Diabetes
In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
STAT1d
Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
BioSpace10d
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
The Associated Press on MSN10d
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
(AP Photo/Amanda Andrade-Rhoades, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Makers of the ...
Indianapolis Business Journal8d
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.